• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

急性症状与 COVID-19 后 8 个月内免疫球蛋白 G 血清阳性之间的关系。

Relationship between Acute-Phase Symptoms and Immunoglobulin G Seropositivity up to Eight Months after COVID-19.

机构信息

Department of Occupational Medicine, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacký University Olomouc, I. P. Pavlova 185/6, 779 00 Olomouc, Czech Republic.

Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University, Salmovská 1, 120 00 Prague, Czech Republic.

出版信息

Medicina (Kaunas). 2022 May 26;58(6):708. doi: 10.3390/medicina58060708.

DOI:10.3390/medicina58060708
PMID:35743971
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9230838/
Abstract

Background and Objectives: Given the limited knowledge of antibody responses to COVID-19 and their determinants, we analyzed the relationship between the occurrence of acute-phase symptoms and infection-induced immunoglobulin (Ig) G seropositivity up to 8 months post-symptom onset. Materials and Methods: In this cross-sectional study, 661 middle-aged unvaccinated healthcare workers (HCWs) were interviewed about the presence of symptoms during the acute phase of their previously confirmed COVID-19 and were tested for specific IgG, targeting the spike protein (S1 and S2). The dependence of seropositivity on the symptom occurrence was explored through multiple logistic regression, adjusted for the interval between symptom onset and serology testing, and through classification and regression trees. Results: A total of 551 (83.4%) HCWs showed seropositivity and, inversely, 110 (16.6%) HCWs were seronegative. The chance of IgG seropositivity was increased by dyspnea (odds ratio (OR) 1.48, p < 0.001) and anosmia (OR 1.52, p = 0.021). Fever in HCWs with dyspnea resulted in the highest detected seropositivity rate, and anosmia in HCWs without dyspnea significantly increased the proportion of seropositivity. Conclusion: Clinical manifestation of the acute phase of COVID-19 predisposes to the development of infection-induced antibody responses. The findings can be applied for assessing the long-term protection by IgG, and thus, for creating effective surveillance strategies.

摘要

背景与目的

鉴于对 COVID-19 抗体反应及其决定因素的了解有限,我们分析了急性症状出现与感染诱导的免疫球蛋白(IgG)血清阳性反应之间的关系,时间范围为症状出现后 8 个月。材料与方法:在这项横断面研究中,对 661 名未接种疫苗的中年医护人员(HCW)进行了访谈,了解他们之前确诊 COVID-19 急性阶段的症状,并针对刺突蛋白(S1 和 S2)检测了特定的 IgG。通过多变量逻辑回归、调整症状出现和血清学检测之间的时间间隔,以及分类和回归树,探索了血清阳性与症状发生的依赖性。结果:共有 551 名(83.4%)HCW 表现出血清阳性,而 110 名(16.6%)HCW 为血清阴性。呼吸困难(比值比(OR)1.48,p<0.001)和嗅觉丧失(OR 1.52,p=0.021)与 IgG 血清阳性的几率增加相关。在有呼吸困难的 HCW 中,发热导致的血清阳性检出率最高,而在无呼吸困难的 HCW 中,嗅觉丧失显著增加了血清阳性的比例。结论:COVID-19 急性阶段的临床表现易导致感染诱导的抗体反应的产生。这些发现可用于评估 IgG 的长期保护作用,从而制定有效的监测策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b92/9230838/3d58c7b3b7a4/medicina-58-00708-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b92/9230838/973478a4b868/medicina-58-00708-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b92/9230838/3d58c7b3b7a4/medicina-58-00708-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b92/9230838/973478a4b868/medicina-58-00708-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b92/9230838/3d58c7b3b7a4/medicina-58-00708-g002.jpg

相似文献

1
Relationship between Acute-Phase Symptoms and Immunoglobulin G Seropositivity up to Eight Months after COVID-19.急性症状与 COVID-19 后 8 个月内免疫球蛋白 G 血清阳性之间的关系。
Medicina (Kaunas). 2022 May 26;58(6):708. doi: 10.3390/medicina58060708.
2
The kinetics and predictors of anti-SARS-CoV-2 antibodies up to 8 months after symptomatic COVID-19: A Czech cross-sectional study.症状性 COVID-19 后长达 8 个月的抗 SARS-CoV-2 抗体的动力学和预测因素:捷克横断面研究。
J Med Virol. 2022 Aug;94(8):3731-3738. doi: 10.1002/jmv.27784. Epub 2022 Apr 22.
3
COVID-19 symptom duration predicts immunoglobulin G seropositivity.COVID-19 症状持续时间可预测免疫球蛋白 G 血清阳性率。
Bratisl Lek Listy. 2021;122(12):861-865. doi: 10.4149/BLL_2021_139.
4
SARS-CoV-2 Incidence, signs and symptoms and main risk factors for COVID-19 infection in Health Care Workers: A hospital-wide survey in Salvador, Brazil.SARS-CoV-2 感染发生率、症状和体征以及 COVID-19 感染的主要危险因素:巴西萨尔瓦多的一项全院调查。
Braz J Infect Dis. 2022 Jul-Aug;26(4):102387. doi: 10.1016/j.bjid.2022.102387. Epub 2022 Jul 21.
5
Difference in SARS-CoV-2 Antibody Status Between Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in Japan.日本 COVID-19 大流行期间癌症患者与医护人员间 SARS-CoV-2 抗体状态的差异。
JAMA Oncol. 2021 Aug 1;7(8):1141-1148. doi: 10.1001/jamaoncol.2021.2159.
6
Higher rate of SARS-CoV-2 IgG seropositivity in hospital-based healthcare workers compared to elderly care staff in a Swedish low-prevalence region: a cross-sectional study.在瑞典低流行地区,与老年护理人员相比,医院医护人员的 SARS-CoV-2 IgG 血清阳性率更高:一项横断面研究。
Infect Dis (Lond). 2021 Nov-Dec;53(12):920-929. doi: 10.1080/23744235.2021.1959949. Epub 2021 Aug 5.
7
Antibody responses to SARS-CoV-2 nucleocapsid and spike proteins in hospitalized patients with COVID-19: A multicenter, retrospective, cross-sectional study in Japan.抗体对 COVID-19 住院患者中 SARS-CoV-2 核衣壳和刺突蛋白的反应:日本多中心、回顾性、横断面研究。
Respir Investig. 2022 Mar;60(2):256-263. doi: 10.1016/j.resinv.2021.11.006. Epub 2021 Dec 3.
8
SARS-CoV-2 IgG response in symptomatic and asymptomatic COVID-19-infected healthcare workers.COVID-19 感染的有症状和无症状医护人员中的 SARS-CoV-2 IgG 反应。
Occup Med (Lond). 2021 Aug 20;71(4-5):215-218. doi: 10.1093/occmed/kqab061.
9
Immunoglobulin-G Antibodies against Severe Acute Respiratory Syndrome - Coronavirus-2 among Health-Care Workers: A Serosurveillance Study from India.医护人员中针对严重急性呼吸综合征冠状病毒2的免疫球蛋白G抗体:一项来自印度的血清学监测研究
Int J Appl Basic Med Res. 2022 Jan-Mar;12(1):18-23. doi: 10.4103/ijabmr.ijabmr_516_21. Epub 2022 Jan 31.
10
Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?接种 COVID-19 疫苗后,人乳中能否检测到 SARS-CoV-2 抗体?
J Pediatric Infect Dis Soc. 2022 Apr 30;11(4):126. doi: 10.1093/jpids/piac024.

本文引用的文献

1
The kinetics and predictors of anti-SARS-CoV-2 antibodies up to 8 months after symptomatic COVID-19: A Czech cross-sectional study.症状性 COVID-19 后长达 8 个月的抗 SARS-CoV-2 抗体的动力学和预测因素:捷克横断面研究。
J Med Virol. 2022 Aug;94(8):3731-3738. doi: 10.1002/jmv.27784. Epub 2022 Apr 22.
2
Neurological complications associated with Covid-19; molecular mechanisms and therapeutic approaches.与新冠病毒相关的神经系统并发症;分子机制与治疗方法。
Rev Med Virol. 2022 Nov;32(6):e2334. doi: 10.1002/rmv.2334. Epub 2022 Feb 9.
3
Clinical update on COVID-19 for the emergency clinician: Presentation and evaluation.
临床更新:COVID-19 对急诊医生的影响:表现与评估。
Am J Emerg Med. 2022 Apr;54:46-57. doi: 10.1016/j.ajem.2022.01.028. Epub 2022 Jan 21.
4
The antibody response to SARS-CoV-2 infection persists over at least 8 months in symptomatic patients.有症状的患者对新冠病毒感染的抗体反应至少持续8个月。
Commun Med (Lond). 2021;1(1):32. doi: 10.1038/s43856-021-00032-0. Epub 2021 Sep 17.
5
Immunity to SARS-CoV-2 up to 15 months after infection.感染后长达15个月对新冠病毒的免疫力。
iScience. 2022 Feb 18;25(2):103743. doi: 10.1016/j.isci.2022.103743. Epub 2022 Jan 7.
6
COVID-19 symptom duration predicts immunoglobulin G seropositivity.COVID-19 症状持续时间可预测免疫球蛋白 G 血清阳性率。
Bratisl Lek Listy. 2021;122(12):861-865. doi: 10.4149/BLL_2021_139.
7
The relationship between COVID-19 viral load and disease severity: A systematic review.新型冠状病毒病病毒载量与疾病严重程度的关系:系统评价。
Immun Inflamm Dis. 2022 Mar;10(3):e580. doi: 10.1002/iid3.580. Epub 2021 Dec 13.
8
Geographic disparities in COVID-19 case rates are not reflected in seropositivity rates using a neighborhood survey in Chicago.使用芝加哥的社区调查,COVID-19 病例率的地域差异并未反映在血清阳性率中。
Ann Epidemiol. 2022 Feb;66:44-51. doi: 10.1016/j.annepidem.2021.10.006. Epub 2021 Oct 31.
9
Prevalence of SARS-CoV-2 antibodies in healthy blood donors from the state of Tyrol, Austria, in summer 2020.2020 年夏季奥地利蒂罗尔州健康献血者中 SARS-CoV-2 抗体的流行情况。
Wien Klin Wochenschr. 2021 Dec;133(23-24):1272-1280. doi: 10.1007/s00508-021-01963-3. Epub 2021 Oct 26.
10
Neurotropism of SARS-CoV-2 and neurological diseases of the central nervous system in COVID-19 patients.SARS-CoV-2 的神经嗜性与 COVID-19 患者中枢神经系统的神经疾病。
Exp Brain Res. 2022 Jan;240(1):9-25. doi: 10.1007/s00221-021-06244-z. Epub 2021 Oct 25.